<DOC>
	<DOCNO>NCT02431260</DOCNO>
	<brief_summary>This study INCB054329 give patient advanced malignancy conduct three treatment group . Each treatment group two part ; dose escalation ( Part 1 ) expansion ( Part 2 ) .</brief_summary>
	<brief_title>An Open-Label , Dose-Escalation Study INCB054329 Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>Confirmed diagnosis advance malignancy : Treatment Group A ( TGA ) : Part 1 : Any advanced solid tumor lymphoma ; Part 2 : Histologically confirm disease specific tumor type Treatment Group B ( TGB ) : Leukemia ( Part 2 acute myeloid leukemia [ AML ] ) , myelodysplastic syndrome ( MDS ) , myelodysplastic /myeloproliferative neoplasm ( MDS/MPN ) myelofibrosis ( MF ) Treatment Group C ( TGC ) : Multiple myeloma Progressed follow least 1 line prior therapy approve therapy available demonstrate prolong survival ( include subject intolerant approve therapy ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Inadequate hematopoietic , liver , endocrine renal function Receipt anticancer medication investigational drug within follow interval first administration study drug : &lt; 6 week mitomycinC nitrosoureas &lt; 28 day investigational agent ( indication ) &lt; 5 halflives anticancer medication , sponsor approval Prior radiotherapy within 2 week prior first dose study drug Untreated brain central nervous system ( CNS ) metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>lymphoma</keyword>
	<keyword>BET bromodomain inhibitor</keyword>
	<keyword>BRD</keyword>
	<keyword>Diffuse large B-cell lymphoma ( DLBCL )</keyword>
	<keyword>Burkitt 's lymphoma</keyword>
	<keyword>c-MYC</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Pancreatic adenocarcinoma</keyword>
	<keyword>castration-resistant prostate cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>NUT midline carcinoma</keyword>
	<keyword>leukemia</keyword>
	<keyword>acute myeloid leukemia ( AML )</keyword>
	<keyword>atypical chronic myeloid leukemia ( aCML )</keyword>
	<keyword>myelodysplastic syndrome ( MDS )</keyword>
	<keyword>myeloproliferative neoplasm</keyword>
	<keyword>myelofibrosis ( MF )</keyword>
	<keyword>multiple myeloma ( MM )</keyword>
	<keyword>CMML</keyword>
	<keyword>MDS/MPN-U</keyword>
	<keyword>RARS-T</keyword>
</DOC>